Epididymo-Orchitis Leading to Testicular Infarction: Revealing a Potentially Severe Complication of SGLT2 Inhibitors
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are not only used for managing type 2 diabetes mellitus (T2DM) but also have been shown to be effective in reducing major cardiovascular events and slowing chronic kidney disease progression. However, they cause glycosuria, which increases the risk f...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American College of Physicians
2025-08-01
|
| Series: | Annals of Internal Medicine: Clinical Cases |
| Online Access: | https://www.acpjournals.org/doi/10.7326/aimcc.2025.0241 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849243666940428288 |
|---|---|
| author | Diego Mateo Cornejo Gonzalez Maria Cristina Cuartas-Mesa Noelle Krueger Hadeel Alfar Rashidat Ashimi |
| author_facet | Diego Mateo Cornejo Gonzalez Maria Cristina Cuartas-Mesa Noelle Krueger Hadeel Alfar Rashidat Ashimi |
| author_sort | Diego Mateo Cornejo Gonzalez |
| collection | DOAJ |
| description | Sodium-glucose cotransporter 2 (SGLT2) inhibitors are not only used for managing type 2 diabetes mellitus (T2DM) but also have been shown to be effective in reducing major cardiovascular events and slowing chronic kidney disease progression. However, they cause glycosuria, which increases the risk for genitourinary (GU) infections. We report a patient with uncontrolled T2DM who developed epididymo-orchitis 6 weeks after starting empagliflozin, which progressed to testicular infarction. Although not well documented, SGLT2 inhibitors may increase the risk for epididymo-orchitis because infections may ascend from the urinary tract. This case highlights the importance of close observation to avoid serious events associated with SGLT2 inhibitors. |
| format | Article |
| id | doaj-art-6ddfa930ff984f799c18e7855a3df318 |
| institution | Kabale University |
| issn | 2767-7664 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | American College of Physicians |
| record_format | Article |
| series | Annals of Internal Medicine: Clinical Cases |
| spelling | doaj-art-6ddfa930ff984f799c18e7855a3df3182025-08-20T03:59:22ZengAmerican College of PhysiciansAnnals of Internal Medicine: Clinical Cases2767-76642025-08-014810.7326/aimcc.2025.0241Epididymo-Orchitis Leading to Testicular Infarction: Revealing a Potentially Severe Complication of SGLT2 InhibitorsDiego Mateo Cornejo Gonzalez0Maria Cristina Cuartas-Mesa1Noelle Krueger2Hadeel Alfar3Rashidat Ashimi41John H. Stroger, Jr. Hospital of Cook County, Department of Internal Medicine, Chicago, Illinois1John H. Stroger, Jr. Hospital of Cook County, Department of Internal Medicine, Chicago, Illinois1John H. Stroger, Jr. Hospital of Cook County, Department of Internal Medicine, Chicago, Illinois1John H. Stroger, Jr. Hospital of Cook County, Department of Internal Medicine, Chicago, Illinois1John H. Stroger, Jr. Hospital of Cook County, Department of Internal Medicine, Chicago, IllinoisSodium-glucose cotransporter 2 (SGLT2) inhibitors are not only used for managing type 2 diabetes mellitus (T2DM) but also have been shown to be effective in reducing major cardiovascular events and slowing chronic kidney disease progression. However, they cause glycosuria, which increases the risk for genitourinary (GU) infections. We report a patient with uncontrolled T2DM who developed epididymo-orchitis 6 weeks after starting empagliflozin, which progressed to testicular infarction. Although not well documented, SGLT2 inhibitors may increase the risk for epididymo-orchitis because infections may ascend from the urinary tract. This case highlights the importance of close observation to avoid serious events associated with SGLT2 inhibitors.https://www.acpjournals.org/doi/10.7326/aimcc.2025.0241 |
| spellingShingle | Diego Mateo Cornejo Gonzalez Maria Cristina Cuartas-Mesa Noelle Krueger Hadeel Alfar Rashidat Ashimi Epididymo-Orchitis Leading to Testicular Infarction: Revealing a Potentially Severe Complication of SGLT2 Inhibitors Annals of Internal Medicine: Clinical Cases |
| title | Epididymo-Orchitis Leading to Testicular Infarction: Revealing a Potentially Severe Complication of SGLT2 Inhibitors |
| title_full | Epididymo-Orchitis Leading to Testicular Infarction: Revealing a Potentially Severe Complication of SGLT2 Inhibitors |
| title_fullStr | Epididymo-Orchitis Leading to Testicular Infarction: Revealing a Potentially Severe Complication of SGLT2 Inhibitors |
| title_full_unstemmed | Epididymo-Orchitis Leading to Testicular Infarction: Revealing a Potentially Severe Complication of SGLT2 Inhibitors |
| title_short | Epididymo-Orchitis Leading to Testicular Infarction: Revealing a Potentially Severe Complication of SGLT2 Inhibitors |
| title_sort | epididymo orchitis leading to testicular infarction revealing a potentially severe complication of sglt2 inhibitors |
| url | https://www.acpjournals.org/doi/10.7326/aimcc.2025.0241 |
| work_keys_str_mv | AT diegomateocornejogonzalez epididymoorchitisleadingtotesticularinfarctionrevealingapotentiallyseverecomplicationofsglt2inhibitors AT mariacristinacuartasmesa epididymoorchitisleadingtotesticularinfarctionrevealingapotentiallyseverecomplicationofsglt2inhibitors AT noellekrueger epididymoorchitisleadingtotesticularinfarctionrevealingapotentiallyseverecomplicationofsglt2inhibitors AT hadeelalfar epididymoorchitisleadingtotesticularinfarctionrevealingapotentiallyseverecomplicationofsglt2inhibitors AT rashidatashimi epididymoorchitisleadingtotesticularinfarctionrevealingapotentiallyseverecomplicationofsglt2inhibitors |